Observational studyAnnals of internal medicine2014
Prevention of vertical transmission of hepatitis B: an observational study.
Observational study in Annals of internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Pooled it
- Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2018Guideline
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatology international · 2016Guideline
- Factors of post-vaccination serological testing coverage among hepatitis B-exposed children in Fujian, China: a population-based cohort study (2021-2023).Frontiers in public health · 2026Article
- The impact of immigration on hepatitis B burden in the United States: a modelling study.Lancet regional health. Americas · 2023Article
- Maternal hepatitis B e antigen can be an indicator for antiviral prophylaxis of perinatal transmission of hepatitis B virus.Emerging microbes & infections · 2021Article
- Hepatitis B vaccine development and implementation.Human vaccines & immunotherapeutics · 2020Article
- Article
- Use of height-independent baseline creatinine imputation method with renal angina index.Pediatric nephrology (Berlin, Germany) · 2019Article
- Efficacy of antepartum administration of hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus.Journal of viral hepatitis · 2019Article
- Stability of hepatitis B viral load during pregnancy and implications for antepartum prophylaxis: A prospective cohort study.Canadian liver journal · 2019Article
- Is hepatitis B antigen in cord blood an immunotolerogen playing a critical role in the pathogenesis of chronic hepatitis B?Human vaccines & immunotherapeutics · 2019Article
- Article
- Peripartum Care for Mothers Diagnosed with Hepatitis B During Pregnancy: A Survey of Provider Practices.Maternal and child health journal · 2018Article
- Poor Sensitivity of Commercial Rapid Diagnostic Tests for Hepatitis B e Antigen in Senegal, West Africa.The American journal of tropical medicine and hygiene · 2018Article
- Global HBV burden: guesstimates and facts.Hepatology international · 2018Review
- Maternal Hepatitis B Infection and Pregnancy Outcomes in the United States: A Population-Based Cohort Study.Open forum infectious diseases · 2018Article
- Review
- Perinatal transmission in infants of mothers with chronic hepatitis B in California.World journal of gastroenterology · 2017Article
- Third-trimester tenofovir to prevent mother-to-child hepatitis B virus transmission.The Indian journal of medical research · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundFor mothers with chronic hepatitis B virus (HBV) infection, the Centers for Disease Control and Prevention recommends immunoprophylaxis to decrease perinatal transmission. However, its effectiveness and risk factors for failure have not been well-studied in community practice.
objectiveTo investigate the effectiveness of a contemporary immunoprophylaxis protocol.
designObservational study.
settingAn HBV perinatal immunoprophylaxis program within Kaiser Permanente Northern California. PATIENTS: 4446 infants born to 3253 HBV-positive mothers between 1997 and 2010. MEASUREMENTS: Adherence to immunoprophylaxis, follow-up testing rates, maternal risk factors for HBV transmission, and transmission rates.
resultsThe infant infection rate was 0.75 per 100 births from 1997 to 2010 (Poisson 95% CI, 0.48 to 1.10). Rates per 100 births were 3.37 (CI, 2.08 to 5.14) for e antigen-positive mothers and 0.04 (CI, 0.001 to 0.24) for e antigen-negative mothers. Among mothers with viral load testing, the lowest level associated with transmission was 6.32 × 107 IU/mL. Infection rates per 100 births were 3.61 (CI, 0.75 to 10.56) among the 83 births to mothers with viral loads of 5 × 107 IU/mL or greater and 0 among the 831 births to mothers with viral loads less than 5 × 107 IU/mL, regardless of e antigen status. LIMITATIONS: Testing for HBV immunity and infection was less complete in earlier years. Viral load testing was only consistently available starting in 2007.
conclusionPrenatal HBV screening followed by postnatal prophylaxis is highly effective in preventing vertical transmission of HBV. A negative e antigen status or a viral load less than 5 × 107 IU/mL (90.9% of women tested) identifies women at extremely low risk for transmission after immunoprophylaxis who are unlikely to benefit from further interventions. PRIMARY FUNDING SOURCE: Kaiser Permanente Community Benefit and National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.